Skip to content
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • Jylamvo
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Media

Logo

Sharon Cunningham : Six Keys to Beating the Odds and Achieving Startup Success

April 19th 2021November 12th 2020

Read More

Logo

How an executive MBA was the catalyst for a pharma start-up

April 19th 2021October 25th 2020

Read More

Logo

Women in pharma face unique obstacles: Shorla Oncology

March 7th 2022September 16th 2020

Read More

Logo

Shorla Oncology – 3 tips for pharma startup success

March 7th 2022June 15th 2020

Read More

Logo

Ireland’s Shorla nabs $8.3M for improved cancer meds to the U.S.

April 19th 2021June 3rd 2020

Read More

Logo

Shorla Oncology Irish Pharmaceutical startup-Tipperary

March 7th 2022May 11th 2020

Read More

Newer posts
Page1 … Page5 Page6
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP
PRIVACY POLICY
Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • Jylamvo
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.